Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19 [0.03%]
pemivartin 组和未接受 pemivartin 治疗的免疫功能低下和非免疫功能低下的受试者的血清病毒中和抗体滴度：一项针对新冠肺炎的长效单克隆抗体临床试验结果
Kristin Narayan,Kazima Tosh,Anna Holmes et al.
Kristin Narayan et al.
Background: Pemivibart received emergency use authorization for COVID-19 prevention in certain individuals with immunocompromise based on immunobridging calculated serum virus-neutralizing antibody (csVNA) titers. We repo...
Letter Reply to "Mind the Postpartum Trough: Closing the Clofazimine Exposure Gap After Delivery in Rifampicin-Resistant Tuberculosis" [0.03%]
论答：重视产后用药空白——应对利福平耐药结核病孕妇在分娩后的氯法齐明暴露空白期
Jennifer A Hughes,Kristina M Brooks,Lee Fairlie et al.
Jennifer A Hughes et al.
In Vitro Selection and Characterization of Tecovirimat-resistant Mpox Virus [0.03%]
体外筛选和表征对抗Tecovirimat的Mpox病毒
Kei Konishi,Haruka Maeda,Misato Shibazaki et al.
Kei Konishi et al.
Background: Mpox virus (MPXV) is the causative agent of mpox, a disease characterized by skin lesions, and remains a global threat since the recent 2022 outbreak. Tecovirimat is an antiviral agent that inhibits MPXV repli...
Proportional Odds or Win Probability as Methods for Assessing Ordinal Outcomes in Infectious Disease Clinical Trials [0.03%]
比例优势或获胜概率：作为评估传染病临床试验中序数结果的方法
Linda J Harrison,Felicia C Chow
Linda J Harrison
Infectious disease trials have long used ordinal outcomes, or ranked categorical scales, to capture the full spectrum of response to an intervention. We review 2 summary statistics for ordinal outcomes: the proportional odds ratio (pOR) and...
Genomic and Clinical Features Associated with Reduced Susceptibility to Cefiderocol and Cross-resistance to β-lactam/β-lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa [0.03%]
头孢迪洛和β-内酰胺/β-内酰胺酶抑制剂的降低敏感性及交叉耐药性的泛菌株系的全球队列的相关基因组和临床特征分析研究
Stephanie L Egge,Donghoon Kang,Nazanin Pouya et al.
Stephanie L Egge et al.
Background: Cefiderocol retains high rates of activity against carbapenem-resistant P. aeruginosa (CRPA) and is being introduced as a last resort antibiotic in developing countries. This study assessed the clinical and ge...
Single-cell RNA sequencing reveals mucosal BPIFA1-high-expressing neutrophils aid immune defense in SARS-CoV-2 breakthrough infection [0.03%]
单细胞RNA测序揭示黏膜BPIFA1高表达的中性粒细胞可帮助SARS-CoV-2突破感染后的免疫防御
Xue Bai,Shixing Chen,Shengxia Yin et al.
Xue Bai et al.
Background: With the viral variants and waning of vaccine-induced immunity over time, SARS-CoV-2 breakthrough infections have become the next challenge following the COVID-19 pandemic, highlighting the need for broader an...
Genetic evidence of cross-border Plasmodium vivax spread in a malaria pre-elimination region of South Asia [0.03%]
南亚疟疾预消除地区间播散的恶性疟原虫遗传证据
Anjana Rai,Edwin Sutanto,Prakash Ghimire et al.
Anjana Rai et al.
Background: Plasmodium vivax is the predominant cause of malaria in South Asia. P. vivax cases have fallen over the past decade, but cross-border transmission remains a major challenge to elimination. Genetic data can gen...
Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice [0.03%]
减毒型裂谷热病毒疫苗诱导小鼠持久保护性免疫且不受性别影响
Karina Mueller Brown,Angel M Kindsvogel,Sarah E Petnuch et al.
Karina Mueller Brown et al.
Background: Rift Valley fever virus (RVFV) is a zoonotic arbovirus endemic to Africa and the Arabian Peninsula that can cause disease in humans and livestock. There are currently no licensed vaccines for human use, but se...
Infants under 24 months with severe malaria have a serological profile of active infection with Epstein Barr Virus [0.03%]
重症疟疾婴幼儿感染Epstein-Barr病毒的血清学特征分析
Wayne T Cheng,Balotin Fogang,Aarti Jain et al.
Wayne T Cheng et al.
Background: Primary Epstein Barr Virus (EBV) infection occurs during late adolescence and is characterized by the symptomatic manifestation of infectious mononucleosis (IM). Primary EBV infection in malaria-endemic areas ...
The Conundrum of Shiga Toxin-Producing Escherichia coli O157:H7 Persistence: Evidence for Locally Persistent Lineages [0.03%]
志贺毒素型大肠杆菌O157:H7长期存在的难题：地方持久系的证据
Gillian A M Tarr,William Finical,Joshua M Rounds et al.
Gillian A M Tarr et al.
Evidence suggests that Shiga toxin-producing Escherichia coli (STEC) strains do not persist at the farm level. We hypothesized that ecosystem-level STEC persistence occurs and contributes significantly to disease burden. We tested this by i...